ArticleMolecular cancer therapeutics2022

Cyclin-dependent Kinase 4/6 Inhibitor Palbociclib in Combination with Ralaniten Analogs for the Treatment of Androgen Receptor-positive Prostate and Breast Cancers.

Amy H Tien et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.